Table 1 Initial patients’ characteristics and outcomes
N (%) [IQR] | |
|---|---|
General characteristics | |
Age, y | 59.7 [49.3; 66.1] |
Sex, No. (%) | |
Female | 20 (21.1) |
Body Mass Index (BMI) | 28.4 [24.7; 32.4] |
Medical history, No. (%) | 46 (48.4) |
Diabetes | 25 (26.3) |
Chronic heart failure | 29 (30.5) |
Chronic respiratory failure | 14 (14.7) |
Chronic renal failure | 15 (15.8) |
Chronic hepatic failure | 2 (2.1) |
Immunosuppression | 23 (24.2) |
Organ transplantation | 11 (47.8) |
Long-term steroid therapy | 7 (30.4) |
HIV infection | 3 (13.0) |
Other | 13 (56.5) |
Characteristics at admission | |
Time from onset of the symptoms to ICU admission, days | 11 [8; 15] |
SAPS 2 | 33 [24; 50] |
SOFA | 6 [4; 8] |
Treatment started within admission and inclusion | |
Antibiotics | 83 (87.4) |
Cephalosporins | 43 (43.9) |
Macrolides | 29 (29.6) |
Cotrimoxazole | 9 (9.2) |
Ureido-penicillins | 7 (7.1) |
Amino-penicillins | 5 (5.1) |
Glycopeptides | 3 (3.1) |
Ciprofloxacin | 3 (3.1) |
Carbapenems | 1 (1) |
Steroids | 61 (64.2) |
Tocilizumab or Anakinra | 28 (29.5) |
Lopinavir/ritonavir | 40 (42.1) |
Remdesivir | 15 (15.8) |
Biological data at ICU admission | |
Lymphocytes, /mm3 | 910 [620; 1220] |
C-reactive protein, mg/L | 138 [65; 218] |
D-Dimer, ng/mL | 1283.5 [682; 4455] |
Ferritin, µg/L | 1352.5 [789; 2372] |
Interleukin-6, pg/mL | 47.6 [20.5; 167.5] |
LDH, IU/L | 481 [344; 638] |
Support therapy in the first 48 h | |
Acute respiratory support | |
Noninvasive positive pressure ventilation, high-flow nasal canula | 58 (61.1) |
Invasive positive pressure ventilation | 27 (28.4) |
Invasive positive pressure ventilation and ECMO | 10 (10.5) |
Renal replacement therapy | 15 (15.8) |
Vasopressor agent support | 41 (43.2) |
Medications during ICU stay | N (%) |
Steroids | 61 (64.2) |
Aciclovir | 19 (20) |
Ganciclovir | 7 (7.4) |
Tocilizumab or Anakinra | 39 (41.1) |
Primary outcome | |
Death at D90 | 42 (44.2) |
Secondary outcomes | |
Death in ICU | 40 (42.1) |
Death in hospital | 42 (44.2) |
Death at D42 | 40 (42.1) |
Nosocomial infections | |
Bloodstream infections | 24 (25.3) |
Nosocomial pneumonia* | 40 (42.1) |
Hospital-acquired pneumonia in non-ventilated patients | 9 (9.5) |
Ventilator-acquired pneumonia | 34 (35.8) |